sparfloxacin has been researched along with clinafloxacin in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (80.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, AJ; Culbertson, TP; Domagala, JM; Gambino, L; Hagen, SE; Karrick, G; Porter, K; Sanchez, JP; Sesnie, JA; Spense, FG | 1 |
| Cohen, MA; Domagala, JM; Gogliotti, RD; Gracheck, SJ; Huband, MD; Sanchez, JP; Sesnie, JA; Shapiro, MA | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Barrett, MS; Erwin, ME; Jones, RN; Koontz, FP | 1 |
| Citron, DM; Goldstein, EJ | 1 |
| Forstall, GJ; Knapp, CC; Washington, JA | 1 |
| Cassell, GH; Crabb, D; Duffy, LB; Pate, MS; Schmid, T; Waites, KB | 1 |
| Jones, RN | 1 |
| Barry, AL; Fuchs, PC | 1 |
| Allen, SD; Barry, AL; Fuchs, PC; Gerlach, EH; Pfaller, MA | 1 |
| Bauernfeind, A | 1 |
| Kaatz, GW; Larsson, AJ; Moody, JA; Rotschafer, JC; Walker, KJ; Zabinski, RA | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Chan, CY; Cheng, AF; Cheung, SW; Lyon, DJ | 1 |
| Borobio, MV; Conejo, M; Perea, EJ; Ramirez, E; Suarez, AI | 1 |
| Donabedian, SA; Perri, MB; Thal, LA; Vazquez, J; Zervos, MJ | 1 |
| Cormican, MG; Jones, RN | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Arvieux, C; Avril, JL; Cartier, F; Jacquelinet, C; Michelet, C; Vu, N | 1 |
| Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K | 1 |
| Brookings, E; Gray, B; Nix, S; Robinson, A; Swiatlo, E; Waites, K | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Fisher, LM; Pan, XS | 1 |
| Hershberger, E; Rybak, MJ | 1 |
2 review(s) available for sparfloxacin and clinafloxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
28 other study(ies) available for sparfloxacin and clinafloxacin
| Article | Year |
|---|---|
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydroxyquinolines; Mice; Microbial Sensitivity Tests; Molecular Structure; Piperazines; Pyrrolidines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1991 |
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; CHO Cells; Cricetinae; Dermatitis, Phototoxic; Drug Design; Female; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 1995 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gentamicins; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium chelonae; Nontuberculous Mycobacteria; Quinolones | 1992 |
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones | 1992 |
Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus | 1991 |
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
Topics: Anti-Infective Agents; Ciprofloxacin; Clindamycin; Culture Media; Erythromycin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Tetracycline; Ureaplasma | 1991 |
Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp.
Topics: 4-Quinolones; Anti-Infective Agents; Fluoroquinolones; Legionella; Naphthyridines; Species Specificity | 1991 |
Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Staphylococcus; Staphylococcus aureus | 1991 |
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1991 |
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1993 |
Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.
Topics: Anaerobiosis; Anti-Infective Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Staphylococcus aureus | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Rapid HPLC assay of clinafloxacin, fleroxacin, levofloxacin, sparfloxacin and tosufloxacin.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Fleroxacin; Fluoroquinolones; Humans; Naphthyridines; Quinolones; Reproducibility of Results | 1994 |
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
Topics: Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1994 |
Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.
Topics: Ampicillin Resistance; Animals; Anti-Infective Agents; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Gram-Positive Bacterial Infections; Quinolones; Rabbits; Random Allocation | 1993 |
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
Topics: Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Fleroxacin; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 1995 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Topics: Amoxicillin; Anti-Infective Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; HeLa Cells; Humans; Levofloxacin; Listeria monocytogenes; Ofloxacin; Quinolones; Rifampin; Sulfamethoxazole; Trimethoprim | 1997 |
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Topics: Animals; Anti-Infective Agents; Bone Marrow; Cells, Cultured; Ciprofloxacin; Cobalt Radioisotopes; Colony-Forming Units Assay; Culture Media, Conditioned; Fleroxacin; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Hemoglobins; Interleukin-3; Leukocyte Count; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Norfloxacin; Ofloxacin; Quinolones; Whole-Body Irradiation | 1997 |
Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Topics: Anti-Infective Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1998 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Fluoroquinolones; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Streptococcus pneumoniae | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |